Why Geron Shares Doubled

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of biotechnology company Geron (NASDAQ: GERN  ) gained as much as 116% this morning after its experimental bone marrow disorder drug helped patients in a study.

So what: In the 18-patient Mayo Clinic study of Geron's imetelstat, 44% experienced clinical improvement, partial remission, or complete remission, triggering plenty of optimism over the drug's blockbuster potential. To be sure, The Street's biotech expert Adam Feuerstein noted that only bone marrow and blood responses were reported -- no clinical or symptomatic responses -- suggesting that Mr. Market might be overreacting to the data.

Now what: Geron will post updated results next month at the American Society of Hematology meeting in New Orleans.

"The current study signifies the potential value of telomerase-based treatment strategies in MF and identifies imetelstat as an active drug in that regard," the study's abstract reads. "The association between response and spliceosome mutations suggests a broader application for the drug in myeloid malignancies."

For lucky Geron shareholders waking up to today's whopping gain, however, taking some dough off the table seems prudent given the seemingly reasonable skepticism surrounding the initial abstract.  

Don't miss out on big gains
The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2013." To find out which stock it is and read our in-depth report, simply click here. It's free!


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2717341, ~/Articles/ArticleHandler.aspx, 4/18/2014 2:17:39 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 5 hours ago Sponsored by:
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASD 4,095.52 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/17/2014 4:00 PM
GERN $1.94 Down -0.03 -1.52%
Geron Corp CAPS Rating: **

Advertisement